Yes its bad corporate governance to mislead the investors quarter after quarter.
More than reducing the revenue guidance disappointment has been in misleading the investors in arv formulations, oncology API, cdmo, inventory destocking etc.
Media should take a lead in grilling the management.
| Subscribe To Our Free Newsletter |
